From November 15 to 16, 2024, the highly anticipated "The first China Pharmaceutical Valley • Future Biological Innovative Drugs Conference" was successfully held in Daxing, Beijing. It was sponsored by the Management Committee of Daxing Bio-pharmaceutical Industry Base of Zhongguacun Science and Technology Park and hosted by Beijing Hotgen Biotech and other enterprises, Beijing Wehand-Bio, MINHAI Biotechnology, JEWIM Pharma, novaBAY, Pharmcube, Biocytogen etc. Academicians, industry experts and representatives of many excellent pharmaceutical enterprises were gathered to discuss the frontier development of the industry, technological breakthroughs and future development of bioinnovative drugs.
The conference focused on the hot topics of "biological innovation technology", "CXO and innovative drugs to the sea", "biomedical innovation, investment and financing" and other industry topics.
Gong Weimi, member of the Leading Party Group and deputy director of the Beijing Municipal Science and Technology Commission and Zhongguancun Management Committee, said in his speech, Beijing has always attached great importance to the development of the medical and health industry, and is carrying out special policies and measures to promote the growth of the industry. Daxing District has been at the forefront of Beijing in terms of medical and health park construction and industrial ecological policies, providing strong support for industrial development.
Xu Jiaqi, former Director of the Center for Drug Evaluation, National Medical Products Administration, presided over the theme report session. He emphasized the potential of Daxing in the future development of China's biomedical industry. It is believed that Daxing will become the core force to promote the development of China's biomedical industry.
Jiang Jiandong, academician of the Chinese Academy of Engineering and president of the Institute of Materia Medica of the Chinese Academy of Medical Sciences, delivered a report on "Star-Shining China's Original New Drugs" and described the bright future of China's innovative drugs. He showed the importance of key targets, and said that we should pursue scientific truth in drug research and development, and also integrate the wisdom of Chinese philosophy.
Li Huiyan, a researcher at the Academy of Military Medicine of the Academy of Military Sciences, shared her insights on the discovery of new immune checkpoint targets and the development of antibody drugs. She said that the use of more advanced technologies such as artificial intelligence would help the research and development of innovative drugs, and she also expected more forces put into it.
Professor Du Jie from Beijing Institute of Cardiovascular and Pulmonary Vascular Diseases, Capital Medical University, introduced the research progress of Sungen Biomedical SGC001, which has the potential to become the world's first antibody drug for myocardial infarction. Professor Liu Yuling, Institute of Materia Medica, Chinese Academy of Medical Sciences & Chinese Union Medical College, shared the innovation and breakthrough of original new drugs in China, by taking the world's first natural hypoglycemic drug "total alkaloids from mulberry branches" as a sample, which contains effective components from plant sources.
In order to further gather the strength of innovative elites in the pharmaceutical industry and promote cooperative innovation in the pharmaceutical field, the conference also held the establishment ceremony of the Bioeconomy Committee of the China Asian Economic Development Association and the China Pharmaceutical Valley Biomedical Industry Alliance. The establishment of the two organizations marked an important step in the coordinated development of bioeconomy and biomedicine industry in our country.
In the subsequent sharing and discussion, the participants gave valuable suggestions for the future development of bioinnovative drugs, from dimensions of innovative technical routes, talent construction, basic platform construction, clinical research, new drugs to the sea, investment and financing etc.
At the roundtable discussion at the end of the conference, guests from Beijing Wehand-Bio, Lapam Capital, Fortune Capital, Cowin Capital, Northern Light Venture Capital, Bayland Capital and other enterprises conducted in-depth discussions on topics such as enterprise survival, changes in innovative enterprise investment standards and going abroad. They called on innovative pharmaceuticals to actively try financing and find new ways, while investment institutions should also do more to empower enterprises to develop better and faster.
For the biomedical industry, innovation is a long-distance race, but it is the only way to obtain key technologies. Through the successful holding of The first China Pharmaceutical Valley • Future Biological Innovative Drugs Conference, Daxing Pharmaceutical Base will continue to establish "science and technology, medicine + finance and service" industrial integration development model. Through the continuous construction of biomedical common technology platform, it will provide financial, industrial, talent, and policy support, promote the park to release the innovative vitality, drive the continuous transformation of innovative achievements, and improve the high-quality development of China's bio-innovative pharmaceutical industry.
Source: China finance and economics
Updated: Dec 17, 2024
